Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Gains from Investment Securities (2020 - 2023)

Ovid Therapeutics' Gains from Investment Securities history spans 4 years, with the latest figure at $12000.0 for Q4 2023.

  • For Q4 2023, Gains from Investment Securities fell 99.92% year-over-year to $12000.0; the TTM value through Sep 2024 reached $12000.0, down 99.92%, while the annual FY2022 figure was $15.8 million, 46.54% up from the prior year.
  • Gains from Investment Securities reached $12000.0 in Q4 2023 per OVID's latest filing, up from -$12000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $15.8 million in Q4 2022 to a low of -$15.8 million in Q2 2022.
  • Average Gains from Investment Securities over 4 years is $1.4 million, with a median of $10000.0 recorded in 2020.
  • The largest YoY upside for Gains from Investment Securities was 230733.43% in 2022 against a maximum downside of 4164.66% in 2022.
  • A 4-year view of Gains from Investment Securities shows it stood at -$488384.0 in 2020, then soared by 419.9% to $1.6 million in 2021, then surged by 914.42% to $15.8 million in 2022, then crashed by 99.92% to $12000.0 in 2023.
  • Per Business Quant, the three most recent readings for OVID's Gains from Investment Securities are $12000.0 (Q4 2023), -$12000.0 (Q1 2023), and $15.8 million (Q4 2022).